Phosphodiesterase 5 inhibitors

被引：22
|
作者：
Stamford, AW [1 ]
机构：
[1] Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA
来源：
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 37 | 2002年 / 37卷
关键词：
D O I：
10.1016/S0065-7743(02)37007-6
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
引用
收藏
页码：53 / 64
页数：12
相关论文
共 50 条
  • [1] Phosphodiesterase 5 inhibitors
    Faure, Sebastien
    ACTUALITES PHARMACEUTIQUES, 2013, 52 (530): : 51 - 54
  • [2] Phosphodiesterase 5 inhibitors: are they cardioprotective?
    Reffelmann, Thorsten
    Kloner, Robert A.
    CARDIOVASCULAR RESEARCH, 2009, 83 (02) : 204 - 212
  • [3] Phosphodiesterase 5 inhibitors and erectile dysfunction
    Sandner, Peter
    Svenstrup, Niels
    Tinel, Hanna
    Haning, Helmut
    Bischoff, Erwin
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2008, 18 (01) : 21 - 33
  • [4] Phosphodiesterase 5 inhibitors for pulmonary hypertension
    Barnes, Hayley
    Brown, Zoe
    Burns, Andrew
    Williams, Trevor
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (01):
  • [5] Symposium 5: Psychopharmacology of phosphodiesterase inhibitors
    Schmidt, C. J.
    BEHAVIOURAL PHARMACOLOGY, 2007, 18 : S7 - S7
  • [6] In Defense of Phosphodiesterase 5 Inhibitors Reply
    Sodhi, Mohit
    Mikelberg, Frederick S.
    Etminan, Mahyar
    JAMA OPHTHALMOLOGY, 2022, 140 (09) : 908 - 909
  • [7] Phosphodiesterase 5 inhibitors and adrenal incidentalomas
    Ilias, Ioannis
    Zabuliene, Lina
    MEDICAL HYPOTHESES, 2019, 130
  • [8] Pharmacology of phosphodiesterase-5 inhibitors
    Corbin, JD
    Francis, SH
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2002, 56 (06) : 453 - 459
  • [9] Phosphodiesterase Inhibitors Type 5 Release
    Pitto, Maria del Pilar Martin
    Capelle, Patrick
    INTERNATIONAL JOURNAL OF SEXUAL HEALTH, 2019, 31 : A358 - A359
  • [10] A chemometric study of phosphodiesterase 5 inhibitors
    Figueiredo, LJD
    Garrido, FMS
    Kunisawa, VYM
    Aboim, CE
    Licks, OB
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2006, 24 (04): : 227 - 232
12345